The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 369 results:
Author Title [ Type(Desc)] Year
Filters: Author is Polyzos, Stergios A  [Clear All Filters]
Journal Article
Polyzos, S. A., Kountouras J., Slavakis A., Zafeiriadou E., Patsiaoura K., Katsiki E., et al. (2013).  A novel noninvasive index for nonalcoholic steatohepatitis: a pilot study.. Biomarkers. 18(7), 607-13.
Polyzos, S. A., Kountouras J., & Mantzoros C. S. (2019).  Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics.. Metabolism. 92, 82-97.
Kountouras, J., Polyzos S. A., Katsinelos P., Kotronis G., & Doulberis M. (2017).  Obesity and the nervous system: more questions.. Lancet Neurol. 16(10), 772-773.
Polyzos, S. A., & Mantzoros C. S. (2019).  Obesity: seize the day, fight the fat.. Metabolism. 92, 1-5.
Polyzos, S. A., Kountouras J., & Mantzoros C. S. (2020).  Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns.. Metabolism. 104, 154144.
Boutari, C., Polyzos S. A., & Mantzoros C. S. (2019).  Of mice and men: Why progress in the pharmacological management of obesity is slower than anticipated and what could be done about it?. Metabolism. 96, vi-xi.
Polyzos, S. A., Makras P., Tournis S., & Anastasilakis A. D. (2019).  Off-label uses of denosumab in metabolic bone diseases.. Bone. 129, 115048.
Vachliotis, I. D., & Polyzos S. A. (2023).  Osteoprotegerin/Receptor Activator of Nuclear Factor-Kappa B Ligand/Receptor Activator of Nuclear Factor-Kappa B Axis in Obesity, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease.. Curr Obes Rep.
Polyzos, S. A., & Mantzoros C. S. (2018).  Outliers of bone metabolic diseases.. Metabolism. 80, 1-4.
Polyzos, S. A., Anastasilakis A. D., & Terpos E. (2009).  Paget's disease of bone: emphasis on treatment with zoledronic acid.. Expert Rev Endocrinol Metab. 4(5), 423-434.
Anastasilakis, A. D., Polyzos S. A., Makras P., Kampas L., Valeri R. Maria, Kyriakoulis D., et al. (2012).  Papillary thyroid microcarcinoma presenting as lymph node metastasis--a diagnostic challenge: case report and systematic review of literature.. Hormones (Athens). 11(4), 419-27.
Makras, P., Polyzos S. A., Papatheodorou A., Kokkoris P., Chatzifotiadis D., & Anastasilakis A. D. (2013).  Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis.. Clin Endocrinol (Oxf). 79(4), 499-503.
Makri, E. S., Xanthopoulos K., Parasidis P. Mavrommati, Makri E., Pettas S., Tsingotjidou A., et al. (2024).  Partial validation of a six-month high-fat diet and fructose-glucose drink combination as a mouse model of nonalcoholic fatty liver disease.. Endocrine.
Polyzos, S. A., Frühbeck G., & Kiortsis D. N. (2023).  Peptide Polyagonists for the Treatment of Nonalcoholic Fatty Liver Disease.. Curr Pharm Des. 29(41), 3263-3265.
Polyzos, S. A., Makras P., Anastasilakis A. D., Mintziori G., Kita M., Papatheodorou A., et al. (2017).  Periostin and sclerostin levels in juvenile Paget's disease.. Clin Cases Miner Bone Metab. 14(2), 269-271.
Polyzos, S. A., & Anastasilakis A. D. (2016).  Periostin on the road to nonalcoholic fatty liver disease.. Endocrine. 51(1), 4-6.
Kountouras, J., Doulberis M., Papaefthymiou A., Polyzos S. A., Vardaka E., Tzivras D., et al. (2019).  A perspective on risk factors for esophageal adenocarcinoma: emphasis on Helicobacter pylori infection.. Ann N Y Acad Sci. 1452(1), 12-17.
Pilitsi, E., Farr O. M., Polyzos S. A., Perakakis N., Nolen-Doerr E., Papathanasiou A-E., et al. (2019).  Pharmacotherapy of obesity: Available medications and drugs under investigation.. Metabolism. 92, 170-192.
Upadhyay, J., Polyzos S. A., Perakakis N., Thakkar B., Paschou S. A., Katsiki N., et al. (2018).  Pharmacotherapy of type 2 diabetes: An update.. Metabolism. 78, 13-42.
Polyzos, S. A., Anastasilakis A. D., Efstathiadou Z. A., Yavropoulou M. P., & Makras P. (2021).  Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations.. Maturitas. 147, 19-25.
Polyzos, S. A., Kountouras J., Zavos C., & Deretzi G. (2011).  The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature.. J Clin Gastroenterol. 45(1), 50-4.
Kountouras, J., Doulberis M., Polyzos S. A., Papaefthymiou A., Kapetanakis N., Arapoglou S., et al. (2018).  Potential Impact of Active Helicobacter pylori Infection with or without Concomitant Metabolic Syndrome on Colorectal Cancer Invasion and Mortality.. Isr Med Assoc J. 20(11), 725-726.
Kountouras, J., Papaefthymiou A., Polyzos S. A., Liatsos C., Tzitiridou-Chatzopoulou M., Chatzopoulos D., et al. (2022).  Potential impact of Helicobacter pylori and metabolic syndrome-related non-alcoholic fatty liver disease on cardio-cerebrovascular disease.. Metabolism. 135, 155276.
Kountouras, C., Polyzos S. A., Stergiopoulos C., Katsinelos P., Tzivras D., Zavos C., et al. (2017).  A potential impact of Helicobacter pylori infection on both obstructive sleep apnea and atrial fibrillation-related stroke.. Sleep Med. 34, 256.
Kountouras, J., Papaefthymiou A., Polyzos S. A., Kazakos E., Tzilves D., Lazaraki G., et al. (2023).  Potential impact of Helicobacter pylori infection on hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B.. J Viral Hepat.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.